News 2015
OBI Pharma Enters Exclusive Agreement with MSD for Rights to DIFICID® (fidaxomicin) in Taiwan
OBI Eligible to Receive Milestone Payments as well as US$3.0 Million Upfront Cash Payment and Royalties on Sales in Taiwan. DIFICID was approved in 2012 by Taiwan’s Department of Health …
OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016
TAIPEI, TAIWAN, August 31/ — OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), announced it plans to unblind its flagship OBI-822/821 (formerly OPT‐822/OPT‐821) Phase 2/3 clinical trial (Protocol Number …
Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015
There has been a lot of discussion about the Progressive Disease (PD) number reported in an erroneous slide deck that was inadvertently uploaded on Monday, 25 May 2015, to the …